Weekly Roundup - PHARMA - 3 February 2025 🔊AstraZeneca’s Calquence Wins FDA Approval as First-Line Treatment for Mantle Cell Lymphoma AstraZeneca’s Calquence (acalbrutinib) received FDA approval for first-line mantle cell lymphoma, showing a ...

🚀 Weekly Roundup - PHARMA - 3 February 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#AstraZeneca #Calquence #Eisai #Biogen #Leqembi #PharmaNews #Biotech #Pharma #Healthcare #ClinicalTrials #Humanteconomy #Humantec #KStrategyand

AstraZeneca’s Calquence Gains Full Approval for Lymphoma, Faces Medicare Price Negotiations AstraZeneca has earned full FDA approval for its lymphoma treatment, Calquence, offering a significant step forward in the fight against mantle cell lymphoma (MCL). Originally granted accelerated appr...

www.linkedin.com/pulse/astraz...

AstraZeneca’s Calquence Gains Full Approval for Lymphoma, Faces Medicare Price Negotiations

kstrategyand.com/pharma-news

#AstraZeneca #Calquence #InflationReductionAct #BTKInhibitor #MedicalBreakthrough #CancerResearch #Humanteconomy #Humantec #KStrategyand

Weekly Roundup - PHARMA - 27 January 2025 🔊AstraZeneca's Calquence Gets Full FDA Approval for Mantle Cell Lymphoma Calquence becomes the first BTK inhibitor approved for first-line treatment of mantle cell lymphoma, offering a 27% progression...

🚀 Weekly Roundup - PHARMA - 27 January 2025

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#AstraZeneca #Calquence #PharmaNews #Biotech #Pharma #Healthcare #ClinicalTrials #Humanteconomy #Humantec